Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2-Reference-Cited by-同舟云学术

Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2

Published:2021-10 Issue:5 Volume:4 Page:854
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Mollica Veronica,Rizzo Alessandro,Massari Francesco^ORCID

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference6 articles.

1. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2021

2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial;Powles;Lancet Oncol,2020

3. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial;Galsky;Lancet,2020

4. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020

5. Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma;McDaniel;Eur Urol Focus,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reevaluating immunotherapy’s potential in first-line metastatic urothelial carcinoma;Journal of Chemotherapy;2024-08-06

2. The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC);Exploration of Targeted Anti-tumor Therapy;2024-07-29

3. Systemtherapie des Urothelkarzinoms der Harnblase;ASCO und EHA 2023, Urothelkarzinom, Nierenzellkarzinom;2023-08-08